Should I get whole exome sequencing for my Pancreatic Cancer

Should You Get Whole Exome Sequencing for Pancreatic Cancer?

This is an excellent question, and the answer depends on what specific information you're trying to get and what testing options your care team has already discussed with you.

What the Current Guidelines Recommend

According to NCCN (National Comprehensive Cancer Network) and ASCO (American Society of Clinical Oncology) guidelines, genetic testing is now standard of care for all newly-diagnosed pancreatic cancer patients, regardless of family history. However, the guidelines focus on two specific types of testing rather than whole exome sequencing:

1. Germline Testing (Hereditary/Inherited Mutations)

This tests your normal cells to see if you inherited a cancer-predisposing mutation. About 10-12% of pancreatic cancer patients carry inherited mutations in genes like:

• BRCA1 and BRCA2
• PALB2
• ATM
• Other DNA repair genes

Why this matters: If you have one of these mutations, it can guide treatment decisions immediately and has implications for your family members.

2. Somatic/Tumor Testing (Mutations in Your Cancer Cells)

This analyzes your tumor tissue to identify mutations that might respond to targeted therapies. The most important findings include:

• KRAS mutations (found in ~87% of pancreatic cancers) - new KRAS inhibitors are now available
• DNA repair deficiencies (BRCA1/2, PALB2 mutations in the tumor) - these respond well to platinum chemotherapy and PARP inhibitors
• Mismatch repair defects - these may respond to immunotherapy (pembrolizumab/Keytruda)
• MTAP deletions - emerging treatment options

Whole Exome Sequencing vs. Targeted Panels

Here's the practical distinction:

Targeted Gene Panels (typically 40-90 genes):

• Focus on genes known to be relevant to pancreatic cancer
• Faster results
• More cost-effective
• Easier to interpret
• Currently recommended by NCCN and ASCO

Whole Exome Sequencing (analyzes ~20,000 genes):

• More comprehensive but generates massive amounts of data
• Many findings are "variants of unknown significance" (VUS) - meaning doctors don't yet know if they matter
• Takes longer to interpret
• More expensive
• Not specifically recommended as first-line testing in current guidelines

What Experts Recommend

According to Dr. [removed] O'Reilly's presentation on "Novel Therapies and New Directions in Pancreas Cancer, 2024":

"You should get 'point of care' genetic testing (hereditary testing on your normal cells and testing on your tumor cells) at your first meeting, accompanied by educational videos to explain the test and its results."

The emphasis is on practical, timely testing that can inform treatment decisions quickly—because with pancreatic cancer, treatment windows are tight.

Questions to Ask Your Oncologist

1. "Have you ordered both germline testing (on my normal cells) and somatic testing (on my tumor)?" - These are the two critical tests recommended by national guidelines.

2. "What specific gene panel are you using, and does it include KRAS, BRCA1/2, PALB2, and mismatch repair genes?" - These are the most actionable findings.

3. "If you recommend whole exome sequencing, what is the clinical reason, and how will the results change my treatment?" - This helps you understand if it's truly necessary for your situation.

4. "Can I get a copy of my molecular profiling report to carry with me?" - This is important for second opinions and future care.

5. "Are there any clinical trials I might be eligible for based on my genetic results?" - This could open up additional treatment options.

The Bottom Line

Standard of care focuses on targeted germline and somatic testing, not whole exome sequencing. These focused panels can identify actionable mutations that directly impact your treatment options—and that's what matters most right now.

Whole exome sequencing might be considered if:

• Your targeted panel results are inconclusive
• Your tumor doesn't have common mutations and your doctor is searching for rare actionable targets
• You're enrolling in a research study that specifically requires it

However, this should be a discussion with your oncology team based on your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.